U.S. Marshals Seize Unapproved Drug From California Maker at FDA’s Request

The Food and Drug Administration May 22 announced that U.S. marshals have seized HybriSil (methylprednisolone acetate 1 percent in silicone gel) from Crescendo Therapeutics LLC at the agency’s request.

HybriSil is an unapproved new drug marketed by Crescendo, the agency said. The seizure, which took place under a warrant issued by the U.S. District Court for the Southern District of California, follows two FDA inspections of Crescendo, which is based in Vista, Calif.

During the first inspection in April 2011, FDA found that Crescendo was marketing HybriSil as a prescription topical corticosteroid, intended to treat scars and skin disorders. FDA ...